Incyte Corp (FRA:ICY)
€ 49.53 -0.85 (-1.69%) Market Cap: 11.18 Bil Enterprise Value: 7.64 Bil PE Ratio: 16.22 PB Ratio: 2.23 GF Score: 84/100

Incyte Corp at Morgan Stanley Healthcare Conference Transcript

Sep 10, 2019 / 04:55PM GMT
Release Date Price: €71.34 (-0.85%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Welcome, everyone. My name is Vikram Purohit. I'm one of the biotech analysts here at Morgan Stanley. And before we start our chat with Incyte, I just need to let everyone know that for all important disclosures, including personal holding disclosures and Morgan Stanley disclosures, all of those appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures, or at the registration desk.

So with that, happy to have with me on the stage, the Chief Medical Officer and Chief Financial Officer from Incyte, Steven Stein and Christiana Stamoulis. Welcome.

So before we get into specific program and financials-related Q&A, maybe you can take a minute for some opening remarks and we'll go from there.

Christiana Stamoulis
Incyte Corporation - Executive VP & CFO

Sure. Happy to start with an update on our progress in 2019. 2019 has been so far a year of strong

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot